SEC Form 4 · accession 0001185185-17-001923
U.S. Stem Cell, Inc. · USRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristin C Comella
Officer — Chief Scientific Officer · Director
Period of report
Aug 7, 2017
Accepted (ET)
Sep 1, 2017 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388319
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.0326 | Aug 7, 2017 | A | 7,500,000 | A | — | Aug 7, 2027 | Common Stock | 7,500,000 | 19,197,746 | D |
| Stock Option (right to buy) | $0.0326 | Aug 7, 2017 | A | 1,500,000 | A | Aug 7, 2017 | Aug 7, 2027 | Common Stock | 1,500,000 | 20,697,746 | D |
Explanation of responses
- F11,875,000 vest on 08/07/2018, 1,875,000 vest on 08/07/2019, 1,875,000 vest on 08/07/2020, 1,875,000 vest on 08/07/2021.